You’ve read about the top 10 molecules with publications from August, but what about the ones we found interesting that didn’t make it into Molecules of the Month? There were five runners-up from August 2022, including:
- a highly selective, dihydropyrimidinone-based CSF1R switch-control kinase inhibitor
- a non-competitive, allosteric CXCR1/2 inhibitor with inflammation-independent antinociceptive effects
- a drug for glioblastoma repurposed as a pan-apicomplexan antiparasitic agent
You can read more about all five molecules in this article, including details about their mechanism of action, their molecular target, indications, and more below.
request a trial
Drug Hunter is commited to helping industry innovators make informed decisions. Premium members have access to our library of the latest stories in science, written by scientists.
Request a trial to access insights powering the pros in our industry.